Future research should focus on (1): Identifying upstream regulators of GPAA1 overexpression in CRC, Such as DNA Methylation or Transcription Factors (2); Testing the efficacy of PARP inhibitors in GPAA1-high CRC xenografts (3); Exploring whether combining GPAA1 silencing with immune checkpoint inhibitors can convert cold tumors to hot tumors and improve therapeutic response. Here, GPAA1 is linked to colorectal carcinoma.